Open Access Open Access  Restricted Access Subscription Access

An Important Parameters of Anti Hyper Lipidemic Drug Such as Pravastatin Include Objectives, Symptoms, Mechanism of Action, Administration, Adverse Effects, Contraindications, Toxicity and Enhancing Health Care Team Outcomes

Muralinath E., Madhavi Latha C., Ramadevi Ch., Sheethal U., Guruprasad M., Karthik Jayanth Y., Renuka U., Sony Sharlet E.

Abstract


Pravastatin is a medication used to treat and control primary hypercholesterolemia, hyperlipidemia, and mixed dyslipidemia. It is a member of the class of hydroxymethylglutaryl coenzyme-A (HMG Co-A) reductase competitive inhibitors. Pravastatin is a helpful drug for managing and treating mixed dyslipidemia, hyperlipidemia, and primary hypercholesterolemia. This activity explains its indications, mode of action, and contraindications. The mechanism of action, side effects, and other crucial elements—such as dosage, pharmacodynamics, pharmacokinetics, monitoring, and pertinent interactions that are important for members of the interprofessional team regarding the treatment and care of patients along with hyperlipidemia and related conditions—will be highlighted in this activity.


Full Text:

PDF

References


National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Pravastatin. In LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK548653/

National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Statins. In LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK548067/

The Medical Letter. (2019). Expanded table: Statins. The Medical Letter on Drugs and Therapeutics, 61(1581), e152.

Wagmann, L., Hemmer, S., Caspar, A. T., & Meyer, M. R. (2020). Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring. Clinical Chemistry and Laboratory Medicine, 58(5), 664–672. https://doi.org/10.1515/cclm-2019-0842

Carmena, R., & Betteridge, D. J. (2019). Diabetogenic action of statins: Mechanisms. Current Atherosclerosis Reports, 21(6), Article 23. https://doi.org/10.1007/s11883-019-0782-4

The Medical Letter. (2019). Lipid-lowering drugs. The Medical Letter on Drugs and Therapeutics, 61(1565), 17–24.

National Institute of Child Health and Human Development. (2024). Pravastatin. In Drugs and Lactation Database (LactMed®). National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK501357/

Gosho, M. (2019). Rhabdomyolysis risk from the use of two-drug combinations of antidyslipidemic drugs with antihypertensive and antidiabetic medications: A signal detection analysis. Fundamental & Clinical Pharmacology, 33(3), 339–346. https://doi.org/10.1111/fcp.12433

Olbricht, C., Wanner, C., Eisenhauer, T., Kliem, V., Doll, R., Boddaert, M., O'Grady, P., Krekler, M., Mangold, B., & Christians, U. (1997). Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clinical Pharmacology & Therapeutics, 62(3), 311–321. https://doi.org/10.1016/S0009-9236(97)90168-4

Wiklund, O., Angelin, B., Bergman, M., Berglund, L., Bondjers, G., Carlsson, A., Lindén, T., Miettinen, T., Odman, B., & Olofsson, S. O. (1993). Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. The American Journal of Medicine, 94(1), 13–20. https://doi.org/10.1016/0002-9343(93)90115-G

Muhammad, Z. A., Ahmad, T., & Baloch, N. (2019). Can alternate-day statin regimen minimize its adverse effects on muscle and tendon? A systematic review. Journal of the Pakistan Medical Association, 69(7), 1006–1013.

Hori, E., Kikuchi, C., Imaeda, K., Okayama, N., Suzuki, T., & Matsunaga, T. (2019). Effect of statins on glycemic status and plasma adiponectin concentrations in patients with type 2 diabetes mellitus and hypercholesterolemia. Yakugaku Zasshi, 139(5), 807–815. https://doi.org/10.1248/yakushi.18-00215

Andrus, M. R., & East, J. (2010). Use of statins in patients with chronic hepatitis C. Southern Medical Journal, 103(10), 1018–1022. https://doi.org/10.1097/SMJ.0b013e3181f2a80d

Charlton, M. (2009). Obesity, hyperlipidemia, and metabolic syndrome. Liver Transplantation, 15(Suppl. 2), S83–S89. https://doi.org/10.1002/lt.21812

Ochs-Balcom, H. M., Nguyen, L. M., Ma, C., Isackson, P. J., Luzum, J. A., Kitzmiller, J. P., Tarnopolsky, M., Weisman, M., Christopher-Stine, L., Peltier, W., Wortmann, R. L., & Vladutiu, G. D. (2019). Clinical features related to statin-associated muscle symptoms. Muscle & Nerve, 59(5), 537–543. https://doi.org/10.1002/mus.26428

Backes, J. M., Ruisinger, J. F., Gibson, C. A., & Moriarty, P. M. (2017). Statin-associated muscle symptoms: Managing the highly intolerant. Journal of Clinical Lipidology, 11(1), 24–33. https://doi.org/10.1016/j.jacl.2016.10.006

Ovesjö, M. L., Skilving, I., Bergman, P., Rane, A., Ekström, L., & Björkhem-Bergman, L. (2016). Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin-induced myopathy. Basic & Clinical Pharmacology & Toxicology, 118(3), 214–218. https://doi.org/10.1111/bcpt.12486


Refbacks

  • There are currently no refbacks.